BiotechTube

sapropterin dihydrochloride

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonurias

Conditions

Phenylketonurias

Trial Timeline

Dec 1, 2004 → Nov 1, 2005

NCT ID
NCT00104260

About sapropterin dihydrochloride

sapropterin dihydrochloride is a phase 2 stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is completed. This product is registered under clinical trial identifier NCT00104260. Target conditions include Phenylketonurias.

What happened to similar drugs?

0 of 3 similar drugs in Phenylketonurias were approved

Approved (0) Terminated (0) Active (3)
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
🔄sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinBioMarin PharmaceuticalPhase 3
🔄Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT00484991Pre-clinicalCompleted
NCT01274026Pre-clinicalCompleted
NCT01141595Pre-clinicalCompleted
NCT00838435Phase 3Completed
NCT00445978Phase 2Completed
NCT00403494Phase 2Completed
NCT00332189Phase 3Completed
NCT00225615Phase 3Completed
NCT00104260Phase 2Completed

Competing Products

7 competing products in Phenylketonurias

See all competitors
ProductCompanyStageHype Score
SapropterinBioMarin PharmaceuticalPre-clinical
23
PegvaliaseBioMarin PharmaceuticalPre-clinical
23
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinBioMarin PharmaceuticalPhase 3
37
Pegvaliase-PqpzBioMarin PharmaceuticalPre-clinical
23
PalynziqBioMarin PharmaceuticalPre-clinical
30
Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37